IRIS
STELLA, STEFANIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.885
EU - Europa 2.494
AS - Asia 2.062
SA - Sud America 399
AF - Africa 336
Continente sconosciuto - Info sul continente non disponibili 183
OC - Oceania 4
Totale 9.363
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.755
SG - Singapore 993
RU - Federazione Russa 871
IT - Italia 778
CN - Cina 451
BR - Brasile 345
IE - Irlanda 222
VN - Vietnam 187
CI - Costa d'Avorio 185
IN - India 126
FR - Francia 90
SE - Svezia 88
UA - Ucraina 87
DE - Germania 85
CA - Canada 84
BD - Bangladesh 62
GB - Regno Unito 62
SN - Senegal 60
KR - Corea 59
FI - Finlandia 44
NG - Nigeria 39
IQ - Iraq 29
PL - Polonia 29
MX - Messico 27
ES - Italia 25
BE - Belgio 24
AR - Argentina 22
NL - Olanda 22
TR - Turchia 22
JP - Giappone 21
ZA - Sudafrica 19
HK - Hong Kong 17
CZ - Repubblica Ceca 16
UZ - Uzbekistan 14
ID - Indonesia 12
MA - Marocco 10
CH - Svizzera 9
IR - Iran 9
AT - Austria 8
CO - Colombia 8
IL - Israele 8
SA - Arabia Saudita 8
AE - Emirati Arabi Uniti 6
EC - Ecuador 6
GR - Grecia 6
KE - Kenya 6
PK - Pakistan 6
PY - Paraguay 6
TT - Trinidad e Tobago 6
EG - Egitto 5
HU - Ungheria 5
KZ - Kazakistan 5
TN - Tunisia 5
AU - Australia 4
LT - Lituania 4
NO - Norvegia 4
PE - Perù 4
PH - Filippine 4
RO - Romania 4
VE - Venezuela 4
BJ - Benin 3
DO - Repubblica Dominicana 3
JM - Giamaica 3
LB - Libano 3
PS - Palestinian Territory 3
RS - Serbia 3
AZ - Azerbaigian 2
BG - Bulgaria 2
CY - Cipro 2
KG - Kirghizistan 2
LV - Lettonia 2
MY - Malesia 2
NP - Nepal 2
OM - Oman 2
TH - Thailandia 2
UY - Uruguay 2
AM - Armenia 1
BO - Bolivia 1
CG - Congo 1
CL - Cile 1
CR - Costa Rica 1
DZ - Algeria 1
ET - Etiopia 1
GD - Grenada 1
GL - Groenlandia 1
GT - Guatemala 1
HN - Honduras 1
HR - Croazia 1
IS - Islanda 1
JO - Giordania 1
LC - Santa Lucia 1
MN - Mongolia 1
NA - Namibia 1
PR - Porto Rico 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 9.180
Salva come PNG Salva come JPEG
Città #
Singapore 651
Santa Clara 530
Dallas 491
Moscow 430
Chandler 326
San Jose 309
Ashburn 240
Chicago 231
Dublin 221
Catania 200
Abidjan 185
Los Angeles 108
Beijing 100
Jacksonville 97
Boardman 85
Hefei 85
Kochi 79
Lauterbourg 65
New York 62
Cambridge 60
Dakar 59
Lawrence 59
Seoul 58
Council Bluffs 57
Andover 55
Civitanova Marche 54
Ho Chi Minh City 48
Palermo 46
Hanoi 43
Milan 39
Buffalo 36
Grafing 35
Nanjing 34
São Paulo 33
Des Moines 31
Toronto 29
Wilmington 29
Montreal 28
The Dalles 27
Dong Ket 26
Columbus 25
Orem 25
Brussels 24
Rome 23
Turku 22
Warsaw 22
Tokyo 21
Bari 20
Abuja 19
Munich 19
San Giovanni la Punta 19
Chennai 18
Johannesburg 17
Lagos 16
Lappeenranta 15
London 15
Hong Kong 14
Brno 13
Brooklyn 13
Messina 13
Ottawa 13
San Mateo 13
Seattle 13
Stockholm 13
Manchester 12
Rio de Janeiro 12
Santa Venerina 12
Belo Horizonte 11
Haiphong 11
Jiaxing 11
Nanchang 11
Amsterdam 10
Baghdad 10
Boston 10
Falls Church 10
Tashkent 10
Aci Catena 9
Bremen 9
Da Nang 9
Denver 9
Phoenix 9
Saint Petersburg 9
San Francisco 9
Atlanta 8
Curitiba 8
Houston 8
Brasília 7
Casablanca 7
Florence 7
Frankfurt am Main 7
Hanover 7
Hebei 7
Helsinki 7
Jakarta 7
Poplar 7
Pune 7
Querétaro 7
Redmond 7
Elk Grove Village 6
Mexico City 6
Totale 6.119
Salva come PNG Salva come JPEG
Nome #
Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib 229
An Optimized NGS Workflow Defines Genetically Based Prognostic Categories for Patients with Uveal Melanoma 212
Activation of the IGF axis in thyroid cancer: Implications for tumorigenesis and treatment 196
Mutational Analysis of BRCA1 and BRCA2 Genes in Breast Cancer Patients from Eastern Sicily 185
A novel system for semiautomatic sample processing in chronic myeloid leukaemia: Increasing throughput without impacting on molecular monitoring at time of sars-cov-2 pandemic 183
AKT Inhibitors: New Weapons in the Fight Against Breast Cancer? 180
High BCR-ABL/GUSISlevels at diagnosis of chronic phase CML are associated with unfavorable responses to standard-dose imatinib 172
Biomarkers and prognostic factors for malignant pleural mesothelioma 171
BCR-ABL1 doubling-times and halving-times may predict CML response to tyrosine kinase inhibitors 171
Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53 165
Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia 163
Efficacy of Dasatinib in a Very Elderly CML Patient Expressing a Rare E13a3 Bcr-Abl1 Fusion Transcript: A Case Report 163
ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives 163
Associations of classic Kaposi sarcoma with common variants in genes that modulate host immunity 163
Impact of the Breakpoint Region on the Leukemogenic Potential and the TKI Responsiveness of Atypical BCR-ABL1 Transcripts 160
A case of high-risk AML in a patient with advanced systemic mastocytosis 159
Colony-forming cell assay detecting the co-expression of JAK2 V617F and BCR-ABL1 in the same clone: A case report 159
Molecular Alterations in Thyroid Cancer: From Bench to Clinical Practice 158
B-ALL relapses after autologous stem cell transplantation associated with a shift from e1a2 to e14a2 BCR-ABL transcripts: A case report 157
Effect of combined epigenetic treatments and ectopic NIS expression on undifferentiated thyroid cancer cells 151
Impact of Different Cell Counting Methods in Molecular Monitoring of Chronic Myeloid Leukemia Patients. 150
Efficacy of Nilotinib in a CML Patient Expressing the Three-way Complex Variant Translocation t(2;9;22) 147
The Q-LAMP Method Represents a Valid and Rapid Alternative for the Detection of the BCR-ABL1 Rearrangement in Philadelphia-Positive Leukemias 145
New insights in thyroid cancer and p53 family proteins 143
Glucose-dependent effect of insulin receptor isoforms on tamoxifen antitumor activity in estrogen receptor-positive breast cancer cells 140
Rufloxacin induced photosensitization in bio-models of increasing complexity 139
Next generation sequencing in a cohort of patients with rare sarcoma histotypes: A single institution experience 139
Mechanistic Translation of Melanoma Genetic Landscape in Enriched Pathways and Oncogenic Protein-Protein Interactions 139
Double-face activity of resveratrol in voluntary runners: assessment of DNA damage by comet assay. 136
Opportunities and challenges of liquid biopsy in thyroid cancer 133
Long-Term Molecular Remission Achieved by Antibody Anti-CD22 and Ponatinib in a Patient Affected by Ph'+ Acute Lymphoblastic Leukemia Relapsed after Second Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report 133
Detection and clinical implications of a novel BCR-ABL1 E12A2 insertion/deletion in a CML patient expressing the E13A2 isoform 133
Molecular Analysis of Luminal Androgen Receptor Reveals Activated Pathways and Potential Therapeutic Targets in Breast Cancer 131
Combined inhibition of bcl2 and bcr-abl1 exercises anti-leukemia activity but does not eradicate the primitive leukemic cells 130
Concomitant and feasible treatment with dasatinib and the anti-EGFR antibody cetuximab plus radiotherapy in a CML patient with multiple squamous neoplasias 129
The role of ponatinib in adult BCR-ABL1 positive acute lymphoblastic leukemia after allogeneic transplantation: a real-life retrospective multicenter study 127
In Silico Prediction of BRCA1 and BRCA2 Variants with Conflicting Clinical Interpretation in a Cohort of Breast Cancer Patients 126
A Multiplex Assay for Fast PIK3CA Hotspot Mutation Characterization in a Single Specimen by 3-Color Digital PCR Analysis 123
Successful management of a pregnant patient with chronic myeloid leukemia receiving standard dose imatinib 122
High BCR::ABL1 Expression Defines CD34+ Cells with Significant Alterations in Signal Transduction, Short-Proliferative Potential and Self-Renewal Ability 121
Potential Therapeutic Targets for Luminal Androgen Receptor Breast Cancer: What We Know so Far 121
Approcci Terapeutici Innovativi per il Trattamento di Cellule di Leucemia Mieloide Cronica Resistenti ad Imatinib Mesilato 120
Rapid decline of philadelphia-positive metaphases after nilotinib treatment in a CML patient expressing a rare e14a3 BCR-ABL1 fusion transcript: A case report 119
No Benefit from Hydroxyurea Pre-Treatment in Frontline Chronic Myeloid Leukemia Therapy and Evidence of Quantitative Changes in the BCR::ABL1 Transcript Level 118
Correlates of Human Herpesvirus-8 DNA detection among adults in Italy without Kaposi sarcoma 118
Prognostic and Therapeutic Roles of the Insulin Growth Factor System in Glioblastoma 116
Suppression of survivin induced by BCR-ABL/JAK2/STAT3 pathway sensitizes imatinib-resistant CML cells to different cytotoxic drugs 114
Second-line dasatinib therapy improved compliance and deep molecular responses in imatinib-intolerant chronic myeloid leukemia patients 114
Uncommon long-term survival in a patient with chronic myeloid leukemia 112
Molecular pathogenesis and treatment perspectives for hypereosinophilia and hypereosinophilic syndromes 112
Effective targeting of breast cancer stem cells by combined inhibition of Sam68 and Rad51 112
Targeting BCL-2 as a therapeutic strategy for primary p210BCR-ABL1-positive B-ALL cells 110
Single-Cell Analysis in the Omics Era: Technologies and Applications in Cancer 101
Prospective assessment of NGS-detectable mutations in CML patients with non-optimal response: the NEXT-in-CML study 98
Imatinib dose escalation to achieve molecular responses in patients with chronic myeloid leukemia in late chronic phase 96
IRF5 is a target of BCR-ABL kinase activity and reduces CML cell proliferation. 96
Influence of complex variant chromosomal translocations in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors 94
THE ROLE OF SPARC IN CHRONIC MYELOID LEUKEMIA 94
The Role of New Technologies in Myeloproliferative Neoplasms 94
Next-generation sequencing improves BCR-ABL1 mutation detection in Philadelphia chromosome-positive acute lymphoblastic leukaemia 93
REThinking the role of the RET oncogene in breast cancer 91
Diagnosis of Chronic Myeloid Leukemia Early in Pregnancy 91
High BCR-ABL/GUS(IS) Levels at Diagnosis Are Associated with Unfavorable Responses to Standard Dose Imatinib 89
The Insulin/IGF System in Colorectal Cancer Development and Resistance to Therapy 89
PI3K inhibition in breast cancer: Identifying and overcoming different flavors of resistance 89
Roles of Interferon Regulatory Factors in Chronic Myeloid Leukemia 87
Personalized strategies for CML patients considering discontinuation of tyrosine kinase inhibitors treatment 75
Bridging the Gap: the role of MDM2 inhibition in overcoming treatment resistance in breast cancer 75
Hyperdiploidy associated with a high BCR-ABL transcript level may identify patients at risk of progression in chronic myeloid leukemia 74
Sequential mutations causing resistance to both Imatinib Mesylate and Dasatinib in a chronic myeloid leukaemia patient progressing to lymphoid blast crisis 74
The other side of the coin: dissecting molecular mechanisms behind hereditary breast cancer in search of therapeutic opportunities 71
Successful Nilotinib therapy in an imatinib-resistant chronic myeloid leukemia patient displaying an intron-derived insertion/truncation mutation in the BCR-ABL kinase domain 68
Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes 66
Integrating Genomic and Clinical Data in AML: Real-World Application of the Sanger Multistage Model 11
Targeting leukemic stem and progenitor cells expressing different BCR::ABL1 levels: antileukemic activity of asciminib with or without TKIs 9
The Coiled Coil and C2 Domains Modulate BCR Localization and BCR-ABL1 Compartmentalization, Transforming Activity and TKI Responsiveness 6
Totale 9.363
Salva come PNG Salva come JPEG
Categoria #
all - tutte 30.554
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 30.554
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022415 0 67 11 7 78 8 64 15 25 11 30 99
2022/20231.036 68 82 56 119 58 148 13 201 209 14 46 22
2023/2024553 44 83 26 24 19 132 8 33 7 23 112 42
2024/20252.107 30 330 79 152 412 291 166 64 75 143 255 110
2025/20264.387 253 240 584 288 657 1.041 442 89 227 288 186 92
2026/2027207 139 68 0 0 0 0 0 0 0 0 0 0
Totale 9.363